Press release
Acromegaly Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Amryt Pharma, Chiasma, Recordati, Novartis, Crinetics Pharma, Camurus AB, Ionis Pharma
DelveInsight's "Acromegaly Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Acromegaly, historical and forecasted epidemiology as well as the Acromegaly market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Acromegaly, offering comprehensive insights into the Acromegaly revenue trends, prevalence, and treatment landscape. The report delves into key Acromegaly statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Acromegaly therapies. Additionally, we cover the landscape of Acromegaly clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Acromegaly treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Acromegaly space.
To Know in detail about the Acromegaly market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acromegaly Market Forecast [https://www.delveinsight.com/sample-request/acromegaly-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key facts of the Acromegaly Market Report:
*
The Acromegaly market size was valued ~USD 1,300 million in 2023 and is to grow with a significant CAGR during the study period (2020-2034)
*
In September 2024, Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today revealed that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for paltusotine, the first once-daily, oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist being developed for the proposed treatment and long-term maintenance therapy of acromegaly.
*
In July 2024, Swedish pharmaceutical company Camurus announced positive outcomes from the Phase III ACROINNOVA 2 study, which evaluated the efficacy and safety of octreotide subcutaneous (SC) depot (CAM2029) in patients with acromegaly.
*
In 2023, the total acromegaly market size in the United States was approximately USD 700 million.
*
In 2023, somatostatin therapies generated the largest market size among all acromegaly treatments in the United States, reaching around USD 500 million, followed by growth hormone antagonists at approximately USD 160 million.
*
In 2023, somatostatin therapies generated the highest revenue among all treatments in the EU4 and the UK, totaling approximately USD 300 million, followed by growth hormone antagonists at around USD 90 million.
*
In the EU4 countries and the UK, the UK accounted for the largest share of the acromegaly market, contributing around 30% of the total market size in these regions.
*
Key Acromegaly Companies: Amryt Pharma/Chiasma, Recordati/Novartis Pharmaceuticals, Crinetics Pharmaceuticals, Camurus AB, Ionis Pharmaceuticals, Ipsen, and others.
*
Key Acromegaly Therapies: MYCAPSSA (octreotide acetate), SIGNIFOR LAR (pasireotide), Paltusotine (CRN 00808), GHR-LRX, CAM2029 (octreotide subcutaneous depot), Lanreotide Autogel Registered , and others.
*
The Acromegaly market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Acromegaly pipeline products will significantly revolutionize the Acromegaly market dynamics.
*
In 2023, the United States had the highest number of diagnosed prevalent cases of acromegaly in the 7MM, with approximately 27,000 cases, followed by Japan with around 9,000 cases.
*
In the United States, gender-specific cases of acromegaly in 2023 were approximately 13,000 in males and around 14,000 in females.
*
In the US, tumor size-specific cases of acromegaly in 2023 were approximately 75% for macroadenomas and 25% for microadenomas, with numbers expected to rise.
*
In the EU4 and the UK, tumor origin-specific cases of acromegaly in 2023 included approximately 20,300 cases from pituitary tumors and around 1,060 cases from non-pituitary tumors.
Acromegaly Overview
Acromegaly is a rare hormonal disorder that occurs when the pituitary gland produces too much growth hormone (GH), typically due to a benign tumor called a pituitary adenoma. This excess GH causes abnormal growth of bones and tissues, leading to enlarged hands, feet, and facial features. Symptoms can develop slowly over years, often resulting in delayed diagnosis. If untreated, acromegaly can lead to serious health complications, including diabetes, hypertension, arthritis, and cardiovascular disease. Treatments include surgery, medication, and radiation therapy to reduce GH levels and manage symptoms.
Get a Free sample for the Acromegaly Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/acromegaly-market [https://www.delveinsight.com/report-store/acromegaly-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Acromegaly Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Acromegaly Epidemiology Segmentation:
The Acromegaly market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
*
Total Prevalence of Acromegaly
*
Prevalent Cases of Acromegaly by severity
*
Gender-specific Prevalence of Acromegaly
*
Diagnosed Cases of Episodic and Chronic Acromegaly
Download the report to understand which factors are driving Acromegaly epidemiology trends @ Acromegaly Epidemiology Forecast [https://www.delveinsight.com/sample-request/acromegaly-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Acromegaly Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acromegaly market or expected to get launched during the study period. The analysis covers Acromegaly market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Acromegaly Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Acromegaly Therapies and Key Companies
*
MYCAPSSA (octreotide acetate): Amryt Pharma/Chiasma
*
SIGNIFOR LAR (pasireotide): Recordati/Novartis Pharmaceuticals
*
Paltusotine (CRN 00808): Crinetics Pharmaceuticals
*
CAM2029 (octreotide subcutaneous depot): Camurus AB
*
GHR-LRX: Ionis Pharmaceuticals
*
Lanreotide A Autogel Registered : Ipsen
Discover more about therapies set to grab major Acromegaly market share @ Acromegaly Treatment Landscape [https://www.delveinsight.com/sample-request/acromegaly-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Acromegaly Market Drivers
*
Increasing Awareness and Diagnosis
*
Advances in Treatment Options
*
Rising Incidence
*
Improved Healthcare Access
*
Government and Regulatory Support
*
Research and Development Investments
Acromegaly Market Barriers
*
High Treatment Costs
*
Diagnostic Challenges
*
Limited Patient Pool
*
Side Effects of Current Therapies
*
Lack of Awareness in Low-income Regions
*
Limited Availability of Specialized Care
Scope of the Acromegaly Market Report
*
Study Period: 2020-2034
*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
*
Key Acromegaly Companies: Amryt Pharma/Chiasma, Recordati/Novartis Pharmaceuticals, Crinetics Pharmaceuticals, Camurus AB, Ionis Pharmaceuticals, Ipsen, and others
*
Key Acromegaly Therapies: MYCAPSSA (octreotide acetate), SIGNIFOR LAR (pasireotide), Paltusotine (CRN 00808), GHR-LRX, CAM2029 (octreotide subcutaneous depot), Lanreotide Autogel Registered , and others
*
Acromegaly Therapeutic Assessment: Acromegaly current marketed and Acromegaly emerging therapies
*
Acromegaly Market Dynamics: Acromegaly market drivers and Acromegaly market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
*
Acromegaly Unmet Needs, KOL's views, Analyst's views, Acromegaly Market Access and Reimbursement
To know more about Acromegaly companies working in the treatment market, visit @ Acromegaly Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/acromegaly-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Acromegaly Market Report Introduction
2. Executive Summary for Acromegaly
3. SWOT analysis of Acromegaly
4. Acromegaly Patient Share (%) Overview at a Glance
5. Acromegaly Market Overview at a Glance
6. Acromegaly Disease Background and Overview
7. Acromegaly Epidemiology and Patient Population
8. Country-Specific Patient Population of Acromegaly
9. Acromegaly Current Treatment and Medical Practices
10. Acromegaly Unmet Needs
11. Acromegaly Emerging Therapies
12. Acromegaly Market Outlook
13. Country-Wise Acromegaly Market Analysis (2020-2034)
14. Acromegaly Market Access and Reimbursement of Therapies
15. Acromegaly Market Drivers
16. Acromegaly Market Barriers
17. Acromegaly Appendix
18. Acromegaly Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=acromegaly-market-forecasted-to-surge-in-coming-years-20242034-analysis-by-delveinsight-amryt-pharma-chiasma-recordati-novartis-crinetics-pharma-camurus-ab-ionis-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Acromegaly Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Amryt Pharma, Chiasma, Recordati, Novartis, Crinetics Pharma, Camurus AB, Ionis Pharma here
News-ID: 3731262 • Views: …
More Releases from ABNewswire
Master Sommelier Tim Gaiser Releases New Book of Wine Essays and Restaurant Tale …
Image: https://www.abnewswire.com/uploads/acfb9c51a1d6241e1ff047040d28e92b.png
RANCHO RIO, NEW MEXICO - Master Sommelier Tim Gaiser, one of less than 300 individuals worldwide to achieve this prestigious title, announces the release of his new book "Strong Water: Tales from a Master Sommelier's Life in Wine and Restaurants." The collection of essays draws from Gaiser's three decades in the wine and restaurant industry, delivering a blend of expert insight, humor, and memorable stories from the front lines…
Video as a Sensor Market worth $101.89 Billion by 2029, at a CAGR of 7.9%
The global Video as a Sensor Market in terms of revenue is estimated to be worth $69.52 billion in 2024 and is poised to reach $101.89 billion by 2029, growing at a CAGR of 7.9% during the forecast period.
The report "Video as a Sensor Market [https://www.marketsandmarkets.com/Market-Reports/video-as-a-sensor-market-66291607.html?utm_source=abnewswire.com&utm_medium=PaidPR&utm_campaign=videoasasensormarket] by Camera Type (IP, Thermal, Machine Vision, Hyperspectral), Sensor (Image Motion, Infrared), Product Type (Video Surveillance, Thermal Imaging, Hyperspectral Imaging, Machine Vision & Monitoring)…
Upgrade Resume Delivers Top-Notch Professional Resume Writing Services to Accele …
Image: https://www.abnewswire.com/uploads/bf13c3f7034b1340552cf23a86f38078.png
Orlando, FL - Upgrade Resume [https://upgraderesume.com/], [https://upgraderesume.com/] a trusted leader in professional resume writing, is revolutionizing the job market by empowering individuals with resumes that open doors and create a lasting impression. Upgrade Resume provides comprehensive services designed to help job seekers across industries secure interviews and achieve their career aspirations.
In today's highly competitive marketplace, a resume is not just a document - it's the first and most critical…
Edge AI software Market Future Trends, New Opportunities, Business Growth, Share …
Edge AI Software Market by Technology (Generative AI, Machine Learning (ML) (Supervised Learning, Reinforcement Learning), Natural Language Processing (NLP), Computer Vision), Data Modality (Spatial Data, Temporal Data) - Global Forecast to 2030.
The global Edge AI software market [https://www.marketsandmarkets.com/Market-Reports/edge-ai-software-market-70030817.html?utm_campaign=edgeaisoftwaremarket&utm_source=abnewswire.com&utm_medium=paidpr] is anticipated to expand at a compound annual growth rate (CAGR) of 24.7%, reaching USD 7.19 billion by 2030, up from an estimated USD 1.92 billion in 2024. Key factors propelling market…
More Releases for Acromegaly
Acromegaly - Drug Pipeline Landscape, 2022
Acromegaly is a rare hormonal condition that results from an excess amount of growth hormone (GH) in the body. The extra amount of GH causes excess growth in the bones and soft tissues of the body. Children with the condition can grow to abnormal heights.
The most common cause of acromegaly is a tumor in your pituitary gland called a pituitary adenoma that causes pituitary gland to release excess growth hormone…
Acromegaly Treatment Market Report Up to 2031
Visiongain has published a new report on Acromegaly Treatment Market Report to 2031: Forecasts By Disease Type (Ectopic Acromegaly and Pseudo Acromegaly), By Drug Class (Somatostatin Analogs (SSAs) (Somatuline Depot and Other SSAs), Dopamine Agonists (Bromocriptine Mesylate and Other Dopamine Agonists), and Growth Hormone Receptor Antagonist (Somavert)), By Route of Administration (Oral and Parenteral), and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online pharmacies) PLUS COVID-19 Recovery Scenarios.
COVID-19 Impact…
Global Acromegaly Market Report Forecast to 2027
Acromegaly is a rare hormonal disease that occurs when the body produces too much growth hormone (GH). The excess GH promotes excessive development in the body's bones and soft tissues. The syndrome causes children to grow to very tall heights. They may also have a disproportionately large bone structure. Acromegaly is a condition that mostly affects the arms, legs, and face.
Get sample copy of this report @ …
Global Acromegaly Market Insights, Forecast
Acromegaly is a hormonal disorder that develops when your pituitary gland produces too much growth hormone during adulthood. When this happens, your bones increase in size, including those of your hands, feet and face. Acromegalyusually affects middle-aged adults. The global Acromegaly market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The…
Acromegaly Treatment Market Opportunity Analysis, 2018-2026
Acromegaly is a rare disorder caused due to the excess production of growth hormone by the pituitary gland, affecting a patient’s physical appearance and internal organs. It is usually caused by benign pituitary tumor (adenoma), however, in rare cases acromegaly symptoms can be observed due to ineffective control of growth hormone-secreting cells by hypothalamus. Abnormal enlargement of hands, arms, feet, legs, and head, and gradual changes in facial features such…
Global Acromegaly Treatment Market (Ectopic Acromegaly & Pseudo Acromegaly)Diagn …
Global acromegaly treatment market was valued at approximately USD +664.0 Million in 2016 and is expected to generate revenue of around USD +838.0 Million by the end of 2022, growing at a CAGR of around +3.94% between 2017 and 2022. There are various symptoms experienced by the patient like the protruded jaw, increased the size of limbs, the spacing between teeth of lower jaw and others. Conditions like hypertension, diabetes,…
